Leukemia, 1751-1759. Nature Publishing Group ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia Leukemia, 34(7), 1751-1759. Nature Publishing Group Leukemia, 34, 7, pp. 1751-1759 Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0 Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP Leukemia, 34, 1751-1759 Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)
Blood Adv Blood advances, 5(4), 1110-1121. American Society of Hematology Blood advances Blood, 5(4), 1110-1121. American Society of Hematology Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, ' Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial ', Blood, vol. 5, no. 4, pp. 1110-1121 . https://doi.org/10.1182/bloodadvances.2020003855 BLOOD ADVANCES Blood Advances, 5(4), 1110-1121. AMER SOC HEMATOLOGY Blood Advances, 5, 1110-1121 Blood advances, 5(4), 1110-1121. The American Society of Hematology Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021) Blood Advances, 5, 4, pp. 1110-1121 Blood, 5(4), 1110-1121. AMER SOC HEMATOLOGY Blood advances, Washington : American Society of Hematology, 2021, vol. 5, no. 4, p. 1110-1121
Leukemia, 29(5), 1041-1050. Nature Publishing Group Leukemia Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Bverloo, H B, Valk, P J M, Kooy, M V, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, M C, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, C, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G & Lowenberg, B 2015, ' Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years ', Leukemia, vol. 29, no. 5, pp. 1041-1050 . https://doi.org/10.1038/leu.2014.332 Leukemia, 29, 5, pp. 1041-50 Leukemia, 29, 1041-50 Leukemia, 29(5), 1041. Nature Publishing Group